C57Bl/6 is a common background for generating genetically modified strains for use in in vivo models of arthritis. While these strains are commonly used, they are also known for requiring larger amounts of induction reagents, present with lower incidence rates and often times a milder disease course. In the classical CIA model, investigators are often required to nearly double the group size to accommodate the incidence rates, which can be as low as 50%.

In the alternative collagen-antibody induced arthritis (CAIA) model, investigators often need to boost the levels of antibody substantially. MD Bioproducts arthritogenic cocktail of four antibodies has been optimized for use in C57Bl/6 strains allowing investigators to induce arthritis in C57Bl/6 with nearly 100% incidence using as low as 2 mg/mouse. Histological data also shows pannus formation, hyperplasia, bone erosion and cellular infiltration in the joints of C57Bl/6 strains with just 2 mg/mouse ArthritoMab™ Antibody Cocktail in just 12 days

Advantages of the CAIA model using ArthritoMab™

• High Incidence rates
• Synchronized Disease
• Susceptible in a variety of strains
• Flexible protocol design
• Rapid 12 day model